You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Previvors Recharge: A Resilience Program for Cancer Previvors

    SBC: Pro-Change Behavior Systems, Inc.            Topic: 102

    It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy

    SBC: BOLDEN THERAPEUTICS, INC.            Topic: R

    PROJECT SUMMARY Alzheimer's disease (AD) is a looming public health crisis that threatens millions of patients' ability to experience healthy aging. In addition to the challenges that AD poses to patients, healthcare providers and caregivers, there is also tremendous economic burden associated with AD and related dementias – estimated to be well over $200B/year in the United States alone. Hundre ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Plans4Care: Personalized Dementia Care On-Demand

    SBC: Plans4Care INC            Topic: R

    PROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Beat Extreme: An Interactive, Tailored Text Messaging Program Combining Extreme Weather Alerts with Hyper-localized Resources and Actionable Insights for Addressing Climate Change

    SBC: Pro-Change Behavior Systems, Inc.            Topic: R

    Summary Climate change is an urgent public health threat, and climate-related health risks disproportionately impact vulnerable populations. Public health agencies have underscored the need to develop scalable and innovative health-equity centered, multi-level interventions that offer tools and resources to 1) raise awareness of the inextricable link between climate change and health and 2) suppor ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Epilepsy Seizure Detection with Innovative Tripolar EEG (tEEG)

    SBC: CREMEDICAL CORP            Topic: NINDS

    PROJECT SUMMARY Electroencephalography (EEG) is an essential component in the evaluation of epilepsy, the most common serious brain disorder worldwide. Misdiagnosis of epilepsy is very common and occurs in up to 50% of the patients. Artifact contamination seriously hinders the effectiveness of EEG and is a root cause of misdiagnosis. CREmedical is developing a tripolar concentric ring electrode (T ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government